SEARCH

SEARCH BY CITATION

Additional Supporting Information may be found in the online version of this article.

FilenameFormatSizeDescription
MDS_25132_sm_SuppTab1.doc75KSupporting Information Table 1. PINK1 (a), PARK2 (b), PARK7 (c) and LRRK2 (d) primers used for PCR amplification and sequencing.
MDS_25132_sm_SuppTab2.doc29KSupporting Information Table 2. Case Summary.
MDS_25132_sm_SuppTab3.doc114KSupporting Information Table 3. Overall proportions of cases with mutations in PARK2, PINK1 and PARK7 (including 95% confidence intervals in brackets).
MDS_25132_sm_SuppTab4.doc54KSupporting Information Table 4. Proportions of PARK2-positive cases among different patient sub-groups (including 95% confidence intervals in brackets).
MDS_25132_sm_SuppTab5.doc43KSupporting Information Table 5. Proportions of PINK1-positive cases among different patient sub-groups (including 95% confidence intervals in brackets).
MDS_25132_sm_SuppTab6.doc34KSupporting Information Table 6. Proportions of PARK7-positive cases among different patient sub-groups (including 95% confidence intervals in brackets).
MDS_25132_sm_SuppTab7.doc30KSupporting Information Table 7. Proportion of cases with PARK2 and PINK1 mutations in different ethnicities (including 95% confidence intervals in brackets).
MDS_25132_sm_SuppTab8.doc95KSupporting Information Table 8. Frequency of homozygous and compound heterozygous mutations in PARK2 and PINK1 (including 95% confidence intervals in brackets).
MDS_25132_sm_SuppInfo.doc81KSupporting Information

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.